ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sanofi is collaborating on diabetes treatments with two new partners. It will pay $300 million up front to work with Lexicon Pharmaceuticals on developing sotagliflozin. The small-molecule inhibitor of sodium-glucose cotransporters 1 and 2 is in Phase III clinical trials. Sanofi also has licensed three long-acting protein- and peptide-based diabetes therapies from Hanmi Pharmaceutical. The South Korean company will receive an initial payment of $430 million from Sanofi. Separately, Hanmi will work with Janssen Pharmaceuticals, part of Johnson & Johnson, to develop an oxyntomodulin-based therapy to treat diabetes and obesity. Janssen will pay $105 million for rights to Hanmi’s lead biologic GLP-1/glucagon dual receptor agonist, which is expected to enter Phase II trials next year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X